ArticleDiscover oncology2025
Ferroptosis and ovarian cancer: a bibliometric study and visualization analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- TFAP2C protects against ferroptosis in ovarian cancer through the KEAP1-NRF2 axis by recruiting HDAC1/2.Oncogene · 2026Article
- Crosstalk between microRNA and oxidative stress in ovarian cancer: diagnosis, pathogenesis and therapeutic resistance.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer ranks first among malignant tumors in the female reproductive system. Ferroptosis plays a crucial role in the occurrence, development, and treatment of ovarian cancer. However, research focusing on the bibliometric analysis of ferroptosis in ovarian cancer remains scarce. This study employs bibliometric methods to analyze research trends related to ferroptosis in the field of ovarian cancer, providing direction for scholars and clinical practitioners.
methodsArticles regarding ferroptosis and ovarian cancer were retrieved from the Web of Science Core Database up to November 6, 2024. After rigorous screening, bibliometric analysis utilized VOSviewer and CiteSpace, while CoreMine facilitated text mining in relation to drugs and genes significantly associated with ovarian cancer and ferroptosis.
resultsThe publication volume of articles on ferroptosis and ovarian cancer has shown a yearly increase, significantly surging after 2022. The three countries with the highest publication outputs are China, the United States, and Japan. The top ten institutions with the most publications are all from China. The ten most frequently mentioned keywords are ferroptosis, ovarian cancer, cell death, apoptosis, expression, death, iron, resistance, metabolism, and cells. Text mining reveals that cisplatin, along with the genes/proteins SLC7A11 and GPX4, significantly correlates with both ovarian cancer and ferroptosis.
conclusionsOur article uses bibliometric methods to reveal publication trends, national distributions, regional collaborations, and recent research hotspots related to the correlation between ferroptosis and ovarian cancer. This study provides objective data as a reference for scientific research and clinical work concerning ferroptosis and ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.